<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379g" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379g/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379g/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379g"><akn:num>379g</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>§ 379g. Definitions
For purposes of this subpart:(1) The term “human drug application” means an application for—(A) approval of a new drug submitted under section 355(b) of this title, or

(B) licensure of a biological product under subsection (a) of section 262 of title 42.


Such term does not include a supplement to such an application, does not include an application with respect to whole blood or a blood component for transfusion, does not include an application with respect to a bovine blood product for topical application licensed before September 1, 1992, does not include an application with respect to an allergenic extract product licensed before October 1, 2022, does not include an application with respect to a standardized allergenic extract product submitted pursuant to a notification to the applicant from the Secretary regarding the existence of a potency test that measures the allergenic activity of an allergenic extract product licensed by the applicant before October 1, 2022, does not include an application with respect to an in vitro diagnostic biologic product licensed under section 262 of title 42, does not include an application with respect to a large volume parenteral drug product approved before September 1, 1992, does not include an application for a licensure of a biological product for further manufacturing use only, and does not include an application or supplement submitted by a State or Federal Government entity for a drug that is not distributed commercially. Such term does include an application for licensure, as described in subparagraph (B), of a large volume biological product intended for single dose injection for intravenous use or infusion.

(2) The term “supplement” means a request to the Secretary to approve a change in a human drug application which has been approved.

(3)(A) The term “prescription drug product” means a specific strength or potency of a drug in final dosage form—(i) for which a human drug application has been </akn:p></akn:content><akn:subsection eId="subsec_379g_1"><akn:num>(1)</akn:num><akn:content><akn:p>(1) The term “human drug application” means an application for— Such term does not include a supplement to such an application, does not include an application with respect to whole blood or a blood component for transfusion, does not include an application with respect to a bovine blood product for topical application licensed before September 1, 1992, does not include an application with respect to an allergenic extract product licensed before October 1, 2022, does not include an application with respect to a standardized allergenic extract product submitted pursuant to a notification to the applicant from the Secretary regarding the existence of a potency test that measures the allergenic activity of an allergenic extract product licensed by the applicant before October 1, 2022, does not include an application with respect to an in vitro diagnostic biologic product licensed under section 262 of title 42, does not include an application with respect to a large volume parenteral drug </akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379g_2"><akn:num>(2)</akn:num><akn:content><akn:p>(2) The term “supplement” means a request to the Secretary to approve a change in a human drug application which has been approved.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379g_3"><akn:num>(3)</akn:num><akn:content><akn:p>(3)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379g_4"><akn:num>(4)</akn:num><akn:content><akn:p>(4) The term “final dosage form” means, with respect to a prescription drug product, a finished dosage form which is approved for administration to a patient without substantial further manufacturing (such as capsules, tablets, or lyophilized products before reconstitution).</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379g_5"><akn:num>(5)</akn:num><akn:content><akn:p>(5) The term “prescription drug establishment” means a foreign or domestic place of business which is at one general physical location consisting of one or more buildings all of which are within five miles of each other and at which one or more prescription drug products are manufactured in final dosage form. For purposes of this paragraph, the term “manufactured” does not include packaging.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379g_6"><akn:num>(6)</akn:num><akn:content><akn:p>(6) The term “process for the review of human drug applications” means the following activities of the Secretary with respect to the review of human drug applications and supplements:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379g_7"><akn:num>(7)</akn:num><akn:content><akn:p>(7) The term “costs of resources allocated for the process for the review of human drug applications” means the expenses in connection with the process for the review of human drug applications for—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379g_8"><akn:num>(8)</akn:num><akn:content><akn:p>(8) The term “adjustment factor” applicable to a fiscal year is the Consumer Price Index for all urban consumers (all items; United States city average) for October of the preceding fiscal year divided by such Index for October 1996.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379g_9"><akn:num>(9)</akn:num><akn:content><akn:p>(9) The term “person” includes an affiliate thereof.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379g_10"><akn:num>(10)</akn:num><akn:content><akn:p>(10) The term “active”, with respect to a commercial investigational new drug application, means such an application to which information was submitted during the relevant period.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>